Axiom Biosciences founder says Hong Kong investors show greater maturity than Nasdaq in handling biotech companies.

Axiom Biosciences founder says Hong Kong investors show greater maturity than Nasdaq in handling biotech companies.

Global biotech firms are increasingly being drawn to Hong Kong for its growing investor base and proximity to Chinese pharmaceutical partners.